These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 35609779)

  • 1. Population pharmacokinetics of polymyxin B and dosage strategy in critically ill patients with/without continuous renal replacement therapy.
    Luo X; Zhang Y; Liang P; Zhu H; Li M; Ding X; Zhang J
    Eur J Pharm Sci; 2022 Aug; 175():106214. PubMed ID: 35609779
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population pharmacokinetics of polymyxin B in critically ill patients receiving continuous venovenous haemofiltration.
    Wang P; Xing H; Zhang F; Liu S; Lu Y; Zhang X; Yang J; Sun T
    Int J Antimicrob Agents; 2022 Jul; 60(1):106599. PubMed ID: 35526750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The population pharmacokinetics and dose optimization of polymyxin B in critically ill patients with or without extracorporeal membrane oxygenation.
    Ye Q; Wang Q; Chen W; Zhang R; Chen Z; Li P; Zhang X; Zhan Q; Wang C
    J Clin Pharm Ther; 2022 Oct; 47(10):1608-1618. PubMed ID: 35716048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A population pharmacokinetic model of polymyxin B based on prospective clinical data to inform dosing in hospitalized patients.
    Hanafin PO; Kwa A; Zavascki AP; Sandri AM; Scheetz MH; Kubin CJ; Shah J; Cherng BPZ; Yin MT; Wang J; Wang L; Calfee DP; Bolon M; Pogue JM; Purcell AW; Nation RL; Li J; Kaye KS; Rao GG
    Clin Microbiol Infect; 2023 Sep; 29(9):1174-1181. PubMed ID: 37217076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population Pharmacokinetic Study of the Suitability of Standard Dosing Regimens of Amikacin in Critically Ill Patients with Open-Abdomen and Negative-Pressure Wound Therapy.
    Carrié C; Delzor F; Roure S; Dubuisson V; Petit L; Molimard M; Breilh D; Biais M
    Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 31964795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determination of vancomycin exposure target and individualized dosing recommendations for critically ill patients undergoing continuous renal replacement therapy.
    Wang C; Chen J; Yang B; Li S; Zhang Y; Chen L; Wang T; Dong Y
    Pharmacotherapy; 2023 Mar; 43(3):180-188. PubMed ID: 36714991
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and Pharmacodynamics of Extended-Infusion Cefepime in Critically Ill Patients Receiving Continuous Renal Replacement Therapy: A Prospective, Open-Label Study.
    Philpott CD; Droege CA; Droege ME; Healy DP; Courter JD; Ernst NE; Harger NJ; Foertsch MJ; Winter JB; Carter KE; Van Fleet SL; Athota K; Mueller EW
    Pharmacotherapy; 2019 Nov; 39(11):1066-1076. PubMed ID: 31549737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population pharmacokinetic and optimization of polymyxin B dosing in adult patients with various renal functions.
    Yu XB; Jiao Z; Zhang CH; Dai Y; Zhou ZY; Han L; Wen X; Sheng CC; Lin GY; Pan JY
    Br J Clin Pharmacol; 2021 Apr; 87(4):1869-1877. PubMed ID: 33002196
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population Pharmacokinetics and Dosing Optimization of Gentamicin in Critically Ill Patients Undergoing Continuous Renal Replacement Therapy.
    He S; Cheng Z; Xie F
    Drug Des Devel Ther; 2022; 16():13-22. PubMed ID: 35023902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population Pharmacokinetic Meta-Analysis and Dosing Recommendation for Meropenem in Critically Ill Patients Receiving Continuous Renal Replacement Therapy.
    Peng Y; Cheng Z; Xie F
    Antimicrob Agents Chemother; 2022 Sep; 66(9):e0082222. PubMed ID: 36005753
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population pharmacokinetics and limited sampling strategies of polymyxin B in critically ill patients.
    Pi MY; Cai CJ; Zuo LY; Zheng JT; Zhang ML; Lin XB; Chen X; Zhong GP; Xia YZ
    J Antimicrob Chemother; 2023 Mar; 78(3):792-801. PubMed ID: 36702748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics, Pharmacodynamics, and Dose Optimization of Cefiderocol during Continuous Renal Replacement Therapy.
    Wenzler E; Butler D; Tan X; Katsube T; Wajima T
    Clin Pharmacokinet; 2022 Apr; 61(4):539-552. PubMed ID: 34792787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens.
    Sandri AM; Landersdorfer CB; Jacob J; Boniatti MM; Dalarosa MG; Falci DR; Behle TF; Bordinhão RC; Wang J; Forrest A; Nation RL; Li J; Zavascki AP
    Clin Infect Dis; 2013 Aug; 57(4):524-31. PubMed ID: 23697744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Case Report: Therapeutic Drug Monitoring of Polymyxin B During Continuous Renal Replacement Therapy in Two Pediatric Patients: Do Not Underestimate Extracorporeal Clearance.
    Xu C; Liu X; Cui Y; Huang X; Wang Y; Fan Y; Wu H; Li X; Guo B; Zhang J; Zhang Y
    Front Pharmacol; 2022; 13():822981. PubMed ID: 35401193
    [No Abstract]   [Full Text] [Related]  

  • 15. Population pharmacokinetics of fluconazole in critically ill patients receiving extracorporeal membrane oxygenation and continuous renal replacement therapy: an ASAP ECMO study.
    Novy E; Abdul-Aziz MH; Cheng V; Burrows F; Buscher H; Corley A; Diehl A; Gilder E; Levkovich BJ; McGuinness S; Ordonez J; Parke R; Parker S; Pellegrino V; Reynolds C; Rudham S; Wallis SC; Welch SA; Fraser JF; Shekar K; Roberts JA
    Antimicrob Agents Chemother; 2024 Jan; 68(1):e0120123. PubMed ID: 38063399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population Pharmacokinetics and Dosing Optimization of Piperacillin-Tazobactam in Critically Ill Patients on Extracorporeal Membrane Oxygenation and the Influence of Concomitant Renal Replacement Therapy.
    Hahn J; Min KL; Kang S; Yang S; Park MS; Wi J; Chang MJ
    Microbiol Spectr; 2021 Dec; 9(3):e0063321. PubMed ID: 34937189
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renal Replacement Therapy as a New Indicator of Voriconazole Clearance in a Population Pharmacokinetic Analysis of Critically Ill Patients.
    Wang Y; Ye Q; Li P; Huang L; Qi Z; Chen W; Zhan Q; Wang C
    Pharmaceuticals (Basel); 2024 May; 17(6):. PubMed ID: 38931333
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population pharmacokinetics of daptomycin in critically ill patients.
    Soraluce A; Asín-Prieto E; Rodríguez-Gascón A; Barrasa H; Maynar J; Carcelero E; Soy D; Isla A
    Int J Antimicrob Agents; 2018 Aug; 52(2):158-165. PubMed ID: 29572042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Levetiracetam dosing in patients receiving continuous renal replacement therapy.
    Chaijamorn W; Charoensareerat T; Rungkitwattanakul D; Phunpon S; Sathienluckana T; Srisawat N; Pattharachayakul S
    Epilepsia; 2021 Sep; 62(9):2151-2158. PubMed ID: 34247386
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimal Meropenem Dosing Regimens in Patients Undergoing Continuous Renal Replacement Therapy: Systematic Review and Monte Carlo Simulations.
    Charoensareerat T; Chaijamorn W; Kerdnimith P; Kosumwisaisakul N; Teeranaew P; Rungkitwattanakul D; Boonpeng A; Srisawat N; Pattharachayakul S
    Blood Purif; 2023; 52(6):503-515. PubMed ID: 37231811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.